Suppr超能文献

[系统性血管炎:修订的命名法,新的治疗策略]

[Systemic vasculitides: revised nomenclature, new therapeutic strategies].

作者信息

Lamprecht P

机构信息

Poliklinik für Rheumatologie, Universität zu Lübeck, Lübeck, Germany.

出版信息

Dtsch Med Wochenschr. 2013 Mar;138(13):651-4. doi: 10.1055/s-0032-1332966. Epub 2013 Mar 19.

Abstract

Vasculitides comprise a heterogeneous group of inflammatory diseases of the blood vessels, which are characterized both by their diversity and an overlap of clinical and pathological findings and manifestations. The etiology of most vasculitides is not yet clear. Their nomenclature and classification is therefore a challenge for internists, immunologists, and pathologists. The revised Chapel Hill Consensus Conference (CHCC) 2012 nomenclature includes an update of the names and definitions of the CHCC 1994 nomenclature. In addition, four new categories were introduced to describe the spectrum of vasculitis comprehensively. Because of the side effects of cytotoxic immunosuppressive agents there is a need for safer and more effective targeted therapies. The first results from studies using biologicals in the treatment of vasculitides are promising.

摘要

血管炎是一组异质性的血管炎症性疾病,其特点是具有多样性,临床和病理表现及发现存在重叠。大多数血管炎的病因尚不清楚。因此,它们的命名和分类对内科学医生、免疫学家和病理学家来说是一项挑战。2012年修订的查珀尔希尔共识会议(CHCC)命名法包括对CHCC 1994年命名法的名称和定义进行更新。此外,还引入了四个新类别以全面描述血管炎的范围。由于细胞毒性免疫抑制剂的副作用,需要更安全、更有效的靶向治疗。使用生物制剂治疗血管炎的首批研究结果很有前景。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验